Emergent BioSolutions Inc. (EBS) Class Action Lawsuit (April 2021)
Closed8:21cv955 • April 19, 2021
Class Period Start
March 9, 2020
Class Period End
February 2, 2022
PSLRA Deadline
June 21, 2021
Case Allegations
10b5
Statutes of Repose
Mar 9, 2023
Country
United States
Court
Federal Court
Settlement Information
Please note that for cases in the settlement stage, claims are handled by the claims administrator and NOT Levi & Korsinsky. Any information or documentation previously provided to us does not constitute submission of a claim. If you need to file a claim, check the status of a claim, or have questions regarding distribution of settlement funds, please contact the claims administrator below.
Claim Deadline
February 4, 2025
Settlement Fund
$40,000,000
Settlement Status
Disbursed
Settlement Class
All persons or entities that purchased or otherwise acquired the common stock of Emergent BioSolutions Inc. (“Emergent”) (NYSE: EBS) between March 10, 2020 and November 4, 2021, both dates inclusive.
Claim Administrator
Strategic Claims Services
P.O. Box 230, 600 N. Jackson St., Ste. 205 Media, PA 19063
+1 866-274-4004
[email protected]
Settlement Website
https://www.strategicclaims.net/emergent/Hearing Date
February 27, 2025
Opt-out Deadline
February 4, 2025
Settlement Note
Download hereProof Of Claim
Download hereDocket History
Jul 3, 2025
Disbursement Approved (opens in a new tab)
The court has approved the distribution of settlement funds to eligible class members. Investors with approved claims may receive payments from the settlement. If you have questions about your claim or payment, contact the claims administrator.
Feb 27, 2025
Final Approval of Settlement (opens in a new tab)
The court has granted final approval of the settlement. Eligible investors who submit valid claims may receive a payment once the claims review and distribution process is completed.
Feb 6, 2025
Motion for Final Approval of Settlement (opens in a new tab)
The parties have asked the court to grant final approval of the proposed settlement. The judge will consider whether the settlement should be approved after reviewing the settlement terms and any objections. If approved, eligible investors who submit valid claims may receive a payment after the claims review and distribution process is completed.
Oct 16, 2024
Proof of Claim Form (opens in a new tab)
To receive your portion of the recovery (if you are eligible), you must submit this form to the claims administrator by the deadline indicated on the form itself. If you do not submit this form in time, you will not be entitled to compensation. If you have questions about how to complete the form, you should contact the claims administrator.
Oct 16, 2024
Oct 4, 2024
Preliminary Approval of Settlement (opens in a new tab)
The court has granted preliminary approval of a proposed settlement. This means the settlement can move forward for further consideration, but it has not yet received final approval. Potential class members will generally receive notice explaining the settlement, their rights, and any deadlines for submitting a claim, objecting to the settlement, or choosing not to participate.
Sep 12, 2024
Motion for Preliminary Approval of Settlement (opens in a new tab)
The parties have asked the court to give preliminary approval to a proposed settlement. The judge will review the request and decide whether the settlement can move forward to the next stage. If approved, potential class members will generally receive information about the settlement and their rights, including any deadlines for taking action.
Jun 18, 2024
Class Certification Granted (opens in a new tab)
The court has determined that a class action is the appropriate method to bring the claims by class members. Usually, when a class is certified, the judge will also affirm an individual or entity to represent the class and finalize a class definition (i.e.: who is represented in the lawsuit).
Feb 9, 2024
Motion for Class Certification (opens in a new tab)
The plaintiffs have asked the court to approve the lawsuit to proceed as a class action on behalf of a group of investors. The judge will decide whether the case meets the requirements for class certification and which investors and claims may be included.
Sep 1, 2023
Motion to Dismiss Denied in Part (opens in a new tab)
The court has determined that plaintiffs have adequately alleged some of their claims, but have failed to adequately allege other claims. The judge has therefore denied in part the motion to dismiss filed by defendants and written an order stating which claims are dismissed and which remain. The case will proceed and parties will litigate the remaining claims.
May 19, 2022
Motion to Dismiss (opens in a new tab)
After reviewing the complaint(s) filed by plaintiffs, defendants have filed a motion requesting that the court dismiss some or all of the plaintiffs' claims. In a motion to dismiss, defendants might challenge the validity of plaintiffs' claims or adequacy of plaintiffs' pleadings. Once a motion to dismiss is filed, the judge will make a decision on whether part or all of the case should be dismissed or the case can proceed as alleged.
Mar 19, 2022
First Amended Complaint (opens in a new tab)
A new complaint has been filed on behalf of certain investors in Emergent BioSolutions Inc.. Amended complaints may contain additional facts, parties, allegations, a change in the class definition, etc.
Mar 9, 2022
Jan 19, 2022
Dec 23, 2021
Appointment of Lead Plaintiff (opens in a new tab)
The court has appointed a lead plaintiff to represent the interests of investors in the lawsuit. The lead plaintiff works with the attorneys handling the case, helps oversee the litigation, and represents the interests of the proposed class.
Jun 2, 2021
Additional Complaint (opens in a new tab)
Another plaintiff has filed a complaint on behalf of investors in Emergent BioSolutions Inc.. The allegations and class definitions are substantively the same.
Apr 19, 2021
First Filed Complaint (opens in a new tab)
A securities fraud class action complaint has been filed on behalf of certain investors in Emergent BioSolutions Inc..